Consistency-Based Approach to Adjust for Multiplicity in Confirmatory Subgroup Analysis

Area of Science:

• Biostatistics
• Clinical Trial Design
• Personalized Medicine

Background:

• Personalized medicine aims for targeted therapies, particularly in oncology, with expected higher efficacy in biomarker-positive patients.
• Biomarker identification limitations and incomplete understanding of their role can lead to non-predictive markers.
• Testing treatments on both overall and biomarker-positive subgroups is crucial but introduces multiplicity issues.

Purpose of the Study:

• To develop a novel statistical approach for hypothesis testing in personalized medicine clinical trials.
• To address type I error inflation arising from testing overall and biomarker-positive patient subgroups simultaneously.
• To create a testing strategy that is both statistically powerful and logically sound for biomarker-driven treatments.

Main Methods:

• Proposed a new statistical method that leverages the logical interconnections between hypothesis tests for overall and subgroup populations.
• Incorporated adjustments for multiplicity by considering different rejection regions.
• Focused on creating a sensible and powerful testing strategy for personalized medicine.

Main Results:

• The proposed method effectively manages multiplicity issues inherent in testing treatments across overall and biomarker-positive patient groups.
• The approach offers a balance between statistical power and logical coherence in hypothesis testing.
• Demonstrates a sensible strategy for evaluating therapies where biomarker predictiveness may be uncertain.

Conclusions:

• A novel statistical method is presented to appropriately adjust for multiplicity in personalized medicine trials.
• The method provides a powerful and sensible approach to testing treatments in both general and specific patient subgroups.
• This contributes to more reliable evaluation of targeted therapies, enhancing clinical trial design.